Robyn Karnauskas
Stock Analyst at Truist Securities
(3.30)
# 1,143
Out of 4,412 analysts
146
Total ratings
44.44%
Success rate
2.4%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $142 → $143 | $131.20 | +8.99% | 8 | Apr 26, 2024 | |
| AMGN Amgen | Reiterates: Buy | $320 | $269.98 | +18.53% | 7 | Apr 12, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $883.20 | +28.51% | 14 | Apr 3, 2024 | |
| BMEA Biomea Fusion | Reiterates: Buy | $55 | $10.78 | +410.20% | 2 | Apr 1, 2024 | |
| OABI OmniAb | Maintains: Buy | $10 | $4.48 | +123.21% | 2 | Mar 26, 2024 | |
| ABSI Absci | Maintains: Buy | $9 | $4.58 | +96.51% | 4 | Mar 26, 2024 | |
| TRML Tourmaline Bio | Reiterates: Buy | $74 | $15.68 | +371.94% | 2 | Mar 25, 2024 | |
| ROIV Roivant Sciences | Reiterates: Buy | $23 | $11.03 | +108.52% | 5 | Mar 25, 2024 | |
| IMVT Immunovant | Reiterates: Buy | $48 | $27.17 | +76.67% | 5 | Mar 25, 2024 | |
| BIIB Biogen | Reiterates: Buy | $340 | $208.90 | +62.76% | 12 | Mar 25, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $50 | $15.55 | +221.54% | 5 | Mar 25, 2024 | |
| LLY Eli Lilly | Reiterates: Buy | $850 | $733.51 | +15.88% | 4 | Mar 22, 2024 | |
| GILD Gilead Sciences | Downgrades: Hold | $91 → $82 | $65.42 | +25.34% | 9 | Feb 22, 2024 | |
| ABBV AbbVie | Maintains: Buy | $180 → $195 | $159.62 | +22.17% | 7 | Feb 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $456 → $508 | $397.48 | +27.81% | 10 | Jan 31, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $12 → $8 | $2.04 | +292.16% | 10 | Jan 23, 2024 | |
| PFE Pfizer | Maintains: Buy | $42 → $36 | $25.40 | +41.73% | 5 | Dec 14, 2023 | |
| CRIS Curis | Initiates: Buy | $26 | $14.47 | +79.68% | 1 | Nov 17, 2023 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $44.85 | +87.29% | 1 | Oct 6, 2023 | |
| PTCT PTC Therapeutics | Downgrades: Hold | $25 | $28.57 | -12.50% | 1 | Oct 6, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | n/a | $2.63 | - | 5 | Oct 5, 2023 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Buy | $140 | $80.91 | +73.03% | 5 | Sep 25, 2023 | |
| NCNA NuCana | Reiterates: Buy | $6 | $4.00 | +50.00% | 2 | Sep 6, 2023 | |
| FATE Fate Therapeutics | Reiterates: Hold | $7 | $3.80 | +84.21% | 3 | Aug 16, 2023 | |
| QURE uniQure | Maintains: Buy | $65 → $55 | $4.53 | +1,114.13% | 1 | May 11, 2023 | |
| MEIP MEI Pharma | Downgrades: Hold | n/a | $3.05 | - | 3 | Dec 6, 2022 | |
| ABCL AbCellera Biologics | Initiates: Buy | $29 | $3.76 | +671.28% | 1 | Nov 16, 2022 | |
| TIL Instil Bio | Maintains: Buy | $500 → $320 | $10.60 | +2,918.87% | 2 | Aug 23, 2022 | |
| KOD Kodiak Sciences | Maintains: Buy | $10 → $15 | $3.28 | +357.32% | 3 | Aug 9, 2022 | |
| DCPH Deciphera Pharmaceuticals | Downgrades: Hold | n/a | $14.65 | - | 3 | Nov 8, 2021 | |
| OPT Opthea | Initiates: Buy | n/a | $3.40 | - | 1 | Nov 11, 2020 | |
| APLT Applied Therapeutics | Initiates: Buy | n/a | $4.28 | - | 1 | Oct 8, 2020 | |
| CALA Calithera Biosciences | Upgrades: Buy | n/a | $0.02 | - | 2 | Feb 16, 2018 |
Merck & Co.
Apr 26, 2024
Maintains: Buy
Price Target: $142 → $143
Current: $131.20
Upside: +8.99%
Amgen
Apr 12, 2024
Reiterates: Buy
Price Target: $320
Current: $269.98
Upside: +18.53%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $883.20
Upside: +28.51%
Biomea Fusion
Apr 1, 2024
Reiterates: Buy
Price Target: $55
Current: $10.78
Upside: +410.20%
OmniAb
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $4.48
Upside: +123.21%
Absci
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $4.58
Upside: +96.51%
Tourmaline Bio
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $15.68
Upside: +371.94%
Roivant Sciences
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.03
Upside: +108.52%
Immunovant
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $27.17
Upside: +76.67%
Biogen
Mar 25, 2024
Reiterates: Buy
Price Target: $340
Current: $208.90
Upside: +62.76%
Arcus Biosciences
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $15.55
Upside: +221.54%
Eli Lilly
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $733.51
Upside: +15.88%
Gilead Sciences
Feb 22, 2024
Downgrades: Hold
Price Target: $91 → $82
Current: $65.42
Upside: +25.34%
AbbVie
Feb 6, 2024
Maintains: Buy
Price Target: $180 → $195
Current: $159.62
Upside: +22.17%
Vertex Pharmaceuticals
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $397.48
Upside: +27.81%
Coherus BioSciences
Jan 23, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $2.04
Upside: +292.16%
Pfizer
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.40
Upside: +41.73%
Curis
Nov 17, 2023
Initiates: Buy
Price Target: $26
Current: $14.47
Upside: +79.68%
Bristol-Myers Squibb Company
Oct 6, 2023
Reiterates: Buy
Price Target: $84
Current: $44.85
Upside: +87.29%
PTC Therapeutics
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $28.57
Upside: -12.50%
BioXcel Therapeutics
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.63
Upside: -
BioMarin Pharmaceutical
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $80.91
Upside: +73.03%
NuCana
Sep 6, 2023
Reiterates: Buy
Price Target: $6
Current: $4.00
Upside: +50.00%
Fate Therapeutics
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $3.80
Upside: +84.21%
uniQure
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $4.53
Upside: +1,114.13%
MEI Pharma
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $3.05
Upside: -
AbCellera Biologics
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $3.76
Upside: +671.28%
Instil Bio
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $10.60
Upside: +2,918.87%
Kodiak Sciences
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.28
Upside: +357.32%
Deciphera Pharmaceuticals
Nov 8, 2021
Downgrades: Hold
Price Target: n/a
Current: $14.65
Upside: -
Opthea
Nov 11, 2020
Initiates: Buy
Price Target: n/a
Current: $3.40
Upside: -
Applied Therapeutics
Oct 8, 2020
Initiates: Buy
Price Target: n/a
Current: $4.28
Upside: -
Calithera Biosciences
Feb 16, 2018
Upgrades: Buy
Price Target: n/a
Current: $0.02
Upside: -